<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Clopidogrel - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Clopidogrel</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Cardiac / Vascular</div>
      <h1>Clopidogrel</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Clopidogrel 75mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>Acute coronary syndrome (ACS) / unstable angina / NSTEMI (typically with ASA)</strong></p>
        <ul>
          <li>Loading: 300 mg PO once (4 x 75 mg tablets) when a loading dose is indicated</li>
          <li>Maintenance: 75 mg PO once daily</li>
        </ul>
        <p><strong>STEMI with suspected thrombolysis pathway (protocol-dependent; often prehospital/remote)</strong></p>
        <ul>
          <li>If &lt; 75 years: 300 mg PO once, then 75 mg PO daily</li>
          <li>If ≥ 75 years: 75 mg PO once (no loading), then 75 mg PO daily</li>
        </ul>
        <p><strong>Secondary prevention (post-MI, ischemic stroke/TIA, peripheral arterial disease) when clopidogrel is selected</strong></p>
        <ul>
          <li>75 mg PO once daily</li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Antiplatelet therapy for ACS (often as dual antiplatelet therapy with ASA) when directed by protocol/medical direction</li>
          <li>Secondary prevention of atherothrombotic events (post-MI, ischemic stroke, PAD) when clopidogrel is selected</li>
          <li>When ASA is contraindicated/intolerant and antiplatelet therapy is still indicated (provider-directed)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <p><strong>Contraindications</strong></p>
        <ul>
          <li>Active pathological bleeding (e.g., GI bleed, intracranial hemorrhage)</li>
          <li>Hypersensitivity to clopidogrel</li>
          <li>Significant hepatic impairment/cholestatic jaundice</li>
        </ul>
        <p><strong>Cautions</strong></p>
        <ul>
          <li>High bleeding risk (recent surgery/trauma, peptic ulcer disease, concomitant anticoagulants)</li>
          <li>Drug interactions that reduce effect (CYP2C19 inhibitors) or increase bleeding risk</li>
          <li>Consider reduced response in CYP2C19 poor metabolizers (if known)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Bleeding/bruising (most common; can be occult)</li>
          <li>GI upset/diarrhea, rash (less common)</li>
          <li>Rare but serious: thrombotic thrombocytopenic purpura (TTP) or severe thrombocytopenia (seek urgent care if suspected)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablets: administer with or without food</li>
          <li>If a loading dose is needed and only 75 mg tablets are stocked: 300 mg load = 4 tablets once</li>
          <li>Avoid "double dosing" if the patient already took clopidogrel—confirm history if possible</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Watch for bleeding: melena, hematemesis, hematuria, easy bruising, hypotension without obvious source</li>
          <li>Consider baseline CBC if starting ongoing therapy; reassess if bleeding/bruising develops</li>
          <li>If severe headache/neuro change: consider intracranial bleed (evac/escalate)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>High consequence of bleeding in remote settings: document dose/time clearly and reassess frequently</li>
          <li>If evacuation/operative care may be needed soon, communicate recent clopidogrel use early</li>
          <li>If a PPI is required for GI protection, avoid strong CYP2C19-inhibiting PPIs when possible; pantoprazole is often used when a PPI is needed (follow local guidance)</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (PDF): https://pdf.hres.ca/dpd_pm/00072260.PDF</li>
          <li>Thrombosis Canada clinical guide (PDF): https://thrombosiscanada.ca/clinical_guides/pdfs/CLOPIDOGREL_42.pdf</li>
          <li>BCEHS drug monograph (operational dosing reference): https://handbook.bcehs.ca/drug-monographs/clopidogrel/</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
